Innovative Trials, an internationally renowned clinical trials patient recruitment company based in the UK, has today ...

Kate Shaw, founder and CEO of Innovative Trials, has responded to data that shows the UK has far fewer women-only clinical ...

The US Food and Drug Administration (FDA) has announced the publication of more than 200 complete response letters (CRLs), ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

The global communications group will unite six agencies under one roof in a purpose-built, hybrid workspace at the heart of ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal’s Zegfrovy (sunvozertinib) to treat a ...

Early commercialisation is one of the most demanding stages in bringing a therapy to market, and the challenges are only ...

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).